OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	628
Towards reparatory measures: blood donation, health systems, and men who have sex with men	517
In the trenches	243
Prioritising health equity alongside donation safety – Authors' reply	228
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	206
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	152
Correction to Lancet Haematol 2023; 10: e333–45	151
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	151
MRD-guided treatment cessation in multiple myeloma	150
Zanubrutinib-associated ecchymotic lesions	150
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	140
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	128
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial	112
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	111
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	109
Blood cell defence against pathogens	100
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	100
Correction to Lancet Haematol 2024; 11: e114–26	100
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	99
Blood deserts: a vision to tackle blood inaccessibility	97
Extensively distributed erythema nodosum in VEXAS syndrome	96
International Society on Thrombosis and Haemostasis Congress 2023	90
Be compliant or compromise?	89
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	87
Production and supply of blood products in Brazil	83

Eltrombopag–cyclosporin A in treating severe aplastic anaemia	82
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	81
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	80
USAID's enduring impact on anaemia management must be preserved	79
Anaemia in a time of climate crisis	74
Coexisting genetic abnormalities and thrombocytopenia	74
Sickle cell disease in India: current status and progress	72
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	71
Correction to Lancet Haematol 2023; 10: e433–44	71
Correction to Lancet Haematol 2025; 12: e294–303	70
Rituximab versus active surveillance in patients with follicular lymphoma	65
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	62
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	62
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	61
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	60
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	60
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	60
Oreofe Odejide—aiming to raise the bar in haematology care	58
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	58
Universal health coverage for children with cancer	58
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	58
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	57
Could improving mental health disorders help increase cancer survival?	56
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	55
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	54
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	50
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	50
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass	50